ClinicalTrials.gg
CompletedNCT03898011Updated Jun 6, 2019

A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions

A Phase 1 interventional study of Lamotrigine and Lamictal in Healthy Adults, sponsored by Pharmtechnology LLC. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-06.

Sponsored by Pharmtechnology LLC · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is an open-labeled, randomized, crossover, two-period, single-center, comparative study, where each participant will be randomly assigned to the reference (Lamictal, 100 mg tablets) or the test (Lamotrigine, 100 mg tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent

Read the detailed description

The objective of this study is to establish if two formulations of lamotrigine are bioequivalent. Also monitoring, registration and evaluation of adverse events that can be performed. The test formulation is Lamotrigine, Tablets 100 mg (Pharmtechnology LLC, Belarus). The reference formulation is Lamictal®, Tablets 100 mg (GlaxoSmithKlein Trading CJSC, Russia).

28 healthy adult volunteers of both genders, with age ranging from 18 to 45 years old, will be divided into two cohorts with equal number of subjects (14). Each participant in a cohort will receive single tablet (100 mg of lamotrigine) of the test or the reference products with 200 ml of water after an overnight fast of at least 10 hours. Participants will fast 4 hours after administration of the study drugs. Next meals will be after 6, 9 and 12 hours after administration of formulations. Standardized meals will be provided in each study period. Water will not be accessible to the participants 1 hour prior to administration of the study drugs and 2 hours after administration of the study drugs in each period.

In each period blood samples will be collected during 30 minutes before dosing and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.5, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 hours after dosing (total number: 23).

The washout period will be 21 days. At the bio-analytical stage, a validated High Performance Liquid Chromatography with tandem Mass Spectrometry detection (HPLC/MS) method will be used to determine plasma concentrations of lamotrigine.

ANOVA will be performed on log transformed pharmacokinetic parameters Cmax, Area Under the pharmacokinetic Curve from the beginning of the study till the time of the last measured concentration (AUC0-t) and 90% confidence interval will be constructed for the ratio of geometric means of the test and the reference products, obtained from the log-transformed data. Bioequivalence will be concluded if the ratio estimate as well as its 90% confidence interval for lamotrigine falls within the acceptable range of 80.00% to 125.00% for Cmax and AUC0-t

02

Conditions studied

  • Healthy Adults

Keywords

  • Bioequivalence
  • Lamotrigine
03

In context

Lead sponsor

Pharmtechnology LLC is the lead sponsor of 27 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy caucasian men or women aged between 18 to 45 years
  • Subjects having no medical history and no clinically significant abnormalities in general physical examination, laboratory assessments and imaging studies
  • 18.5-30 kg/m² with body mass >45 kg and ≤100 kg
  • Non-breastfeeding women
  • Non-pregnant women (negative pregnancy test)
  • If subject is a female and is of , she should be practicing an acceptable non-hormonal method of for the duration of the study(the entire time from the moment of signing the form and within 14 days after the completion of the study), such as a combination of male condom and diaphragm with spermicide
  • If subject is a male and has a female partner of childbearing potential, he should be practicing an acceptable method of birth control for the duration of the study(the entire time from the moment of signing the informed consent form and within 14 days after the completion of the study), such as a double barrier method of birth control or sexual continence during the whole study and within 14 days after its' completion
  • Subjects are able to understand the requirements of the study, to sign a written informed consent, and also to accept all the restrictions imposed during the course of the study, and to agree to return for the required investigations

Exclusion criteria

Exclusion Criteria:

  • Subjects with a known history of allergic disorders
  • to lamotrigine or to any of the of the test and the reference product
  • Lactase deficiency, lactose intolerance, glucose-galactose malabsorption
  • Subjects with a known history of drug intolerance
  • Dehydration due to diarrhea, vomiting, or another cause in the last 24 hours before the beginning of the first period of the study
  • Subjects with history of psychiatric disorders
  • History of convulsions, epilepsy and any other neurological disorders
  • Adherence to any low sodium diet for 2 weeks before starting research, or adherence to a special diet (for example, vegetarian, vegan, with restriction of the use of salt) or lifestyle (work at night, extreme physical exertion)
  • Use of gestagen-containing injectable hormonal , implants, intrauterine hormonal therapeutic systems within 6 months prior to start of the study
  • Female subjects of child bearingpotential having unprotected intercourse with an unsterilized sexual partner within 30 days prior to start of the study
  • Consumption of xanthine-containing foods and drinks (tea, coffee, coca-cola, chocolate), alcohol, products containing poppy within 72 hours prior to start of the first period of the study
  • Consumption of citrus fruits (including grapefruit and grapefruit juice) and cranberries (including cranberry juice and other cranberry drinks) within 14 days prior to start of the study
  • Acute and chronic cardiovascular, respiratory, gastrointestinal diseases, neuroendocrine disorders, renal and/or hepatic impairment, blood system disorders
  • Other conditions which, according to the researcher's judgment, may affect absorption, distribution, biotransformation and elimination of any formulation or increase risks of deterioration of volunteer's condition
  • Surgical interventions on the gastrointestinal tract with the exception of appendectomy
  • Acute infectious diseases less than 4 weeks prior to the start of the study
  • abnormalities
  • Sitting systolic blood pressure \< 100 mm Hg or > 130 mm Hg and/or sitting diastolic blood pressure \< 70 mm Hg or > 90 mm Hg
  • Heart rate \<60 or >90 beats per minute at screening check-in
  • Use of liver enzyme inducers and inhibitors, in particular isoenzyme (inducers: omeprazole, cimetidine, products containing the extract of Hypericum perforatum, barbiturates, carbamazepine, phenytoin, ; inhibitors: antiviral drugs, clarithromycin, ciprofloxacin, gestodene etc.) within 2 months prior to the start of the study
  • Use of any systemic drugs within 14 days prior to the start of the study
  • Use of Over-The-Counter (OTC) drugs, including herbs and nutritional supplements within 7 days prior to the First Dosing Date (including vitamins and natural food additives, phyto supplements,herbal preparations such as, cat's claw, angelica officinalis, oenothera, feverfew, garlic, ginger, ginkgo, red clover, horse chestnut, green tea, ginseng)
  • Donation of plasma or blood (450 ml or more) within 2 months prior to the start of the study
  • Intake of more than 10 units alcohol per week (1 unit of alcohol is equivalent to ½ liter of beer, 200 ml dry wine or 50 ml of spirits) or history of alcoholism, drug addiction, drug abuse
  • Smoking more than 10 cigarettes per day
  • Participation in other clinical trials of medicines within 3 months prior to the start of the study
  • Positive test for syphilis, , or
  • Positive pregnancy test (for female subjects with child bearing potential)
  • Breast-feeding
  • In the case of using of oral hormonal contraceptives, they should be withdrawn 2 months prior to the start of the study
  • Positive test for alcohol in exhaled air
  • Positive urinary screen test for the content of narcotic and potent substances during screening and at each arrival at the research stage
  • Volunteers who don't intend to comply with the study protocol and/or not credible therein and who are, at the discretion of the Principal Investigator, unable to understand and assess the information about the study, expected risks and possible discomfort in the process of signing written
  • The values of standard laboratory and instrumental parameters that go beyond the reference values of the local clinical laboratory
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Other
    Sequence Test-Reference (TR)

    14 participants (total number of enrolled volunteers - 28) assigned to sequence TR will receive a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 1 and a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.

    Drug: Lamotrigine · Drug: Lamictal

  • Other
    Sequence Reference-Test (RT)

    14 participants (total number of enrolled volunteers - 28) assigned to sequence RT will receive a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 1 and a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.

    Drug: Lamotrigine · Drug: Lamictal

Interventions

  • Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus

    Also known as: the test product

  • Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia

    Also known as: the reference product

06

What researchers measure

Primary outcomes

  1. Cmax of lamotrigine for the test and the reference products

    Maximum concentration in plasma among observed concentrations at pre-specified time points

    Time frame: Time points: 0,00 (within 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75.3.00, 3.5, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 hours after dosing

  2. AUC0-t of lamotrigine for the test and the reference products

    Area under the plasma concentration versus time curve from time 0 to the last measured concentration

    Time frame: Time points: 0,00 (within 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75.3.00, 3.5, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 hours after dosing

Secondary outcomes

  1. AUC0-∞ of lamotrigine for the test and the reference products

    Area under the plasma concentration versus time curve from time 0 to infinite time

    Time frame: Time points: 0,00 (within 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75.3.00, 3.5, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 hours after dosing

  2. Tmax of lamotrigine for the test and the reference products

    Time to maximum measured plasma concentration

    Time frame: Time points: 0,00 (within 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75.3.00, 3.5, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 hours after dosing

  3. T1/2 of lamotrigine for the test and the reference products

    Elimination or terminal half-life

    Time frame: Time points: 0,00 (within 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75.3.00, 3.5, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 hours after dosing

  4. Kel of lamotrigine for the test and the reference products

    Elimination rate constant

    Time frame: Time points: 0,00 (within 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75.3.00, 3.5, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 hours after dosing

  5. AUCresid% of lamotrigine for the test and the reference products

    Residual area under the pharmacokinetic curve from the time of the last measured concentration to infinity time

    Time frame: Time points: 0,00 (within 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75.3.00, 3.5, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 hours after dosing

  6. Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol

    An AE is defined as any untoward medical occurrence in a subject administered the test or the reference product and which does not necessarily have a causal relationship with the treatment.

    Time frame: Up to 27 days

07

Study locations

1 site
  • State Autonomous Healthcare Facility of the Yaroslavl Region "Clinical Hospital No. 2"
    Yaroslavl, Yaroslavl Region 150010, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in May 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2019
First posted
Apr 1, 2019
StartActual
Mar 23, 2019
Primary completionActual
May 4, 2019
CompletionActual
May 4, 2019
Last update
Jun 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03898011
Collaborators
ClinPharmInvest, LLC
Responsible party
Sponsor
First posted
Apr 1, 2019
Start date
Mar 23, 2019
Primary completion
May 4, 2019
Completion
May 4, 2019
Last update
Jun 6, 2019

Study contacts

Alexander Khokhlov
principal investigator · ClinPharmInvest, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion